Latest Conference Articles

There are many possible approaches to helping overweight and obese patients. A recent study suggests one possible approach in this work could be mindfulness-based stress reduction.

There are many ways to approach the problem of obesity. One new option is group therapy, bringing together many facets of treatment.

Testosterone is not significantly associated with bone mineral density or fracture risk. Estrone, however, may have a role in bone health and fracture prevention in postmenopausal women.

Study results show teriparatide therapy results in changes to bone microarchitecture that, although not associated with decreased estimated bone strength, have an unknown effect on fracture risk.

Long-term denosumab therapy was associated with better outcomes compared to calcium and vitamin D supplementation alone in postmenopausal women with osteoporosis.

One of the major concerns of people considering quitting smoking is whether they will gain weight. A new study has shown that may not need to be a concern and that the overall benefits to their health can outweigh the risks.

For many years expectant mothers have been told to avoid smoking. A new study reinforces those lessons and also shows the potential complications of secondhand smoke.

There are many factors that go into determining a child's IQ but a recent study determined that the health of a mother's thyroid could play at least a small part in that overall process.

As more diabetes drugs hit the market there are natural safety questions that come with these prescriptions. In recent years the US Food and Drug Administration has worked to increase the steps taken to ensure the safety of these drugs.

Bariatric surgery has been shown to reduce the long-term risk of diabetes-associated vascular disease in obese patients. According to study results presented at ENDO 2015, bariatric surgery reduced the risk of developing macrovascular events by 20% and reduced the risk of microvascular events by 50%.

Analysis indicates that current measures may underestimate predicted adult height in obese girls, and overestimate predicted adult height in obese boys.

In overweight and obese individuals without diabetes, liraglutide 3.0 mg as an adjunct to diet and exercise was associated with greater reductions in fasting and postprandial glucose compared with diet and exercise alone.

Study results show that patients who underwent Roux-en-Y gastric bypass surgery experienced greater and more rapid weight loss at 12- and 24 months post-surgery compared to patients who received the sleeve gastrectomy procedure. GB patients also experienced a larger decrease in hemoglobin within the first two months post-surgery and a sustained decrease in creatinine.

In many states the sale of electronic cigarettes is not as regulated as the more traditional method making it an option for many young potential users.

When grass allergies are at their peak patients are usually at their lowest when forced to go outside. An early study looked at the role of immunotherapy in helping patients in the future.

introducing peanuts to children at a young age could prevent the development of allergies.

Chronic kidney disease developed in association with exposure to antiretrovirals in people with initially normal levels of estimated glomerular filtration rate (eGFR) was not limited to increased incidence immediately after starting therapy but in fact increased over time and exposure.

Tenofovir alafenamide, which results in 90% lower circulating plasma tenofovir than standard tenofovir disoproxil fumarate, is associated with similar virologic response rates as the standard regimen, but with an improved safety profile.

Combination treatment with daclatasvir and asunaprevir plus interferon/ribavirin had high success rates in a 24-week clinical trial for treatment of hepatitis C in patients coninfected with HIV.

An interferon/ribavirin-free pill that combines two drugs to treat patients with certain genotypes of hepatitis C who are also infected with HIV was found to be highly effective in a 12-week trial, clearing the hepatitis C virus from almost all the patients involved.

Novel second-generation HIV-1 maturation inhibitor shows favorable antiviral activity and safety profile in HIV-1, subtype B-infected subjects

Study results show that treatment with atorvastatin lowers LDL-cholesterol levels and reduces the volume of noncalcified and high-risk plaques in HIV-infected patients with subclinical atherosclerosis.

Cultural barriers, poor treatment adherence, and other factors thwart efforts to provide effective anti-HIV acquisition measures for women in Africa.

A high dose of rifampin and moxifloxacin in combination with standard drug treatment could cut the length of time needed to successfully treat patients for tuberculosis.

Pre-exposure prophylaxis (PrEP) is a strategy with significant historical precedent in the infectious disease field. Applied to HIV prevention, at-risk individuals would take PrEP to protect against HIV acquisition in case of any planned or unplanned exposure, potentially permitting HIV prophylactic control by the uninfected individual.

Bristol-Myers Squibb today announced that its Phase III clinical trial of a combination product daclatasvir-sofosbuvir showed dramatic cure rates for patients infected with both HIV and Hepatitis C. The results of the trial, known as ALLY-2, were presented at the 2015 Conference on Retroviruses and Opportunistic Infections in Seattle, WA.

Disappointing study results showed that precoital vaginal gel containing tenofovir does not prevent HIV acquisition in women, in part because of poor adherence during the clinical trial.

The high cure rate associated with new drugs approved to treat chronic hepatitis C has stirred debate about the relevance of early diagnosis and treatment of the acute stage of this infectious liver disease.

The future of HIV treatment may include decentralized testing and self-testing, treatment optimization, improved diagnostics, home-delivered antiretroviral therapy, and other advances.

Today, there are multiple combinations of interferon-free treatments that have efficacy rates of 90% or higher and are better tolerated with fewer severe side effects than previous interferon-based therapies.